Corrigendum to ‟Repurposing FDA-approved drugs to fight COVID-19 using in silico methods: Targeting SARS-CoV-2 RdRp enzyme and host cell receptors (ACE2, CD147) through virtual screening and molecular dynamic simulationsˮ [Inform. Med. Unlocked 23 (2021) 1-9/100541]
Main Authors: | Soodeh Mahdian, Mahboobeh Zarrabi, Yunes Panahi, Somayyeh Dabbagh Sadeghpour |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-01-01
|
Series: | Informatics in Medicine Unlocked |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352914823001077 |
Similar Items
-
Repurposing FDA-approved drugs to fight COVID-19 using in silico methods: Targeting SARS-CoV-2 RdRp enzyme and host cell receptors (ACE2, CD147) through virtual screening and molecular dynamic simulations
by: Soodeh Mahdian, et al.
Published: (2021-01-01) -
Inhibition of HEV Replication by FDA-Approved RdRp Inhibitors
by: Preeti Hooda, et al.
Published: (2023-10-01) -
Triple targeting of human IMPDH, SARS-CoV-2 RdRp, and Rhizopus oryzae RdRp: An in silico perspective
by: Abdel-moniem S. Hassan, et al.
Published: (2023-12-01) -
Snapshots of a Non-Canonical RdRP in Action
by: Diego S. Ferrero, et al.
Published: (2021-06-01) -
SARS-CoV-2 RdRp Inhibitors Selected from a Cell-Based SARS-CoV-2 RdRp Activity Assay System
by: Jung Sun Min, et al.
Published: (2021-08-01)